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Abstract
Since the 1920s, menthol has been added to cigarettes and used as a characterizing flavor. The health effects of
cigarette smoking are well documented, however the health effects of menthol cigarettes as compared to non-
menthol cigarettes is less well studied. This review discusses menthol’s effects on 1) biomarkers of tobacco smoke
exposure, 2) toxicity and cellular effects, 3) lung function and respiration, 4) pulmonary and/or vascular function, 5)
allergic reactions and inflammation, and 6) tobacco-related diseases. It is concluded that menthol is a biologically
active compound that has effects by itself and in conjunction with nicotine, however much of the data on the
other areas of interest are inconclusive and firm conclusions cannot be drawn.
Introduction
Tobacco use produces a myriad of negative health
effects, and has caused more than 5 million premature
deaths through diseases such as cancer, cardiovascular
disease, and respiratory disease [1]. Given the large
number of menthol cigarette users (nearly 27% of cur-
rent smokers, with Black/African American smokers
being about 3 times more likely to smoke menthol
cigarettes as compared to white smokers [2,3]) there is
less information on the health of effects of menthol
cigarettes as compared to non-menthol cigarettes than
might be expected. Indeed, although there are many
research articles that point to menthol as a possible con-
tributing factor to several health effects of smoking, the
majority did not investigate menthol as an independent
factor and instead focused on racial/ethnic disparities on
use. This review seeks to explore the available literature
on the health effects of menthol cigarettes as compared
to non-menthol cigarettes. Questions addressed in this
review include:
￿ What, if any, are menthol’s effects on biomarkers of
tobacco smoke exposure?
￿ What effect, if any, does menthol have on a cellular
level?
￿ What effect, if any, does menthol have on
respiration?
￿ What effect, if any, does menthol have on cardiovas-
cular function?
￿ What allergic reactions have been associated with
menthol cigarettes?
￿ What effect, if any, does menthol have on smoking-
related disease?
Summarized in this review are 89 articles found to
have either direct relevance to these questions, or were
used to provide relevant background information. Many
o ft h e s ea r t i c l e sw e r ei d e n t i f i e dt h r o u g har e v i e wo ft h e
literature conducted by the National Cancer Institute in
2009, published as “Bibliography of literature on
menthol and tobacco” http://cancercontrol.cancer.gov/
tcrb/documents/menthol_bibliography_508.pdf. Search
terms used were menthol cigarette(s); mentholated
cigarette(s); menthol tobacco; mentholated tobacco;
menthol smoker(s); menthol AND the following terms:
addiction, nicotine, marketing, cancer, biomarkers,
asthma, cardiovascular disease, heart disease, vascular
disease, chronic obstructive lung disease, respiratory,
environmental tobacco smoke, national health, health
disparities, and minority health. Additional searches and
sources, such as those identified through review articles,
identified additional articles that were included as
appropriate. A publication or study is identified as hav-
ing a tobacco industry association if one or more
authors were employees of the tobacco industry, as
identified by author affiliation on the publication.
Of those articles that are in the NCI Bibliography
but were not included, most were not directly relevant
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independent from tobacco smoke exposure, did not
evaluate menthol as a separate variable). Some of those
articles, however, were used to provide background
information. Animal or in vitro research was included
only to help explain human findings. Although a few
review articles were used to make general statements
and/or provide background information, most were
not included in deference to original sources. Pub-
lished abstracts were not included out of concern that,
due to the lack of details, those studies could not ade-
quately be assessed.
Biomarkers of tobacco smoke exposure in
menthol and nonmenthol smokers
Nicotine
Inhalation of drugs is a very effective means of delivery
because inhaled drugs avoid first-pass metabolism by
the liver, which rapidly metabolizes nicotine through the
enzyme cytochrome P450 (CYP2A6). The main metabo-
lite of nicotine is cotinine, and cotinine concentrations
in blood, urine, or saliva are often used as biomarkers to
evaluate tobacco use and exposure to environmental
tobacco smoke [4-6]. Cotini n eh a sal o n g e rh a l f - l i f e
(average 18-20 hours) than does nicotine (2-3 hours)
[5], making it a more feasible marker of tobacco use
than nicotine. Cotinine is further metabolized to trans-
3’-hydroxycotinine (3 HC). Although glucuronidation (a
process by which glucuronic acid is conjugated with a
substrate) is usually a minor metabolic pathway for
nicotine and cotinine, it can be a major determinant of
nicotine clearance in people who have low CYP2A6
activity. That is, in people who metabolize nicotine
more slowly through the CYP2A6 pathway, the glucuro-
nidation pathway may metabolize a larger share of nico-
t i n e .T h u s ,g l u c u r o n i d a t i o nm a yb e c o m eam o r e
significant factor in overall nicotine metabolism. Slower
metabolism of nicotine means that levels of nicotine in
t h eb o d yr e m a i ne l e v a t e df o ral o n g e rp e r i o do ft i m e ,
allowing a longer timeframe for nicotine to interact with
nicotinic receptors all over the body.
The authors of a small cross-over study of seven
Black/African American and seven White smokers
found that menthol cigarette smoking resulted in slower
nicotine metabolism and slower total nicotine clearance.
Overall, there were no significant racial/ethnic differ-
ences in the disposition kinetics of nicotine [7]. Menthol
cigarette smoking was associated with reduced nicotine
metabolism through a decrease in CYP2A6 enzyme
activity and a substantial reduction in glucuronidation.
These findings were supported in an in vitro study
using human microsomes that reported that menthol
inhibits the CYP2A6 enzyme, resulting in inhibition of
nicotine metabolism [8].
Using data from a study of 755 Black/African Ameri-
can smokers who smoked fewer than 10 cigarettes a day
(so-called “light” smokers), Ho and colleagues [9] found
that smokers who smoke menthol cigarettes had slower
metabolism of cotinine as compared to non-menthol
smokers.
Clark et al [10] studied the effects of menthol cigar-
ettes on biochemical markers of smoke exposure among
161 adult Black/African American and White smokers
in a cross-sectional study. There were also racial/ethnic
differences, with African American smokers having sig-
nificantly higher cotinine per cigarette ratios, but it is
unknown if this is due to differences in metabolism,
smoking behavior, or other reasons. After adjusting for
race, cigarettes per day and average amount of each
cigarette smoked, serum cotinine levels were signifi-
cantly higher among menthol cigarette smokers than
among smokers of non-menthol cigarettes, suggesting
greater exposure to nicotine. [10] Numerous other
reports [4,10-15] have found that Black/African Ameri-
can smokers are more likely than White smokers to
smoke fewer cigarettes per day (CPD) yet have substan-
tially higher cotinine levels. Because Black/African
American individuals are considerably more likely to
smoke menthol cigarettes, menthol may have been a
mitigating factor; however, the potential impact of
menthol was not evaluated separately in these studies.
In a between-subjects study of 95 female adult smo-
kers stratified by race/ethnicity and menthol/non-
menthol cigarette preference, Ahijevych and Parsley [11]
reported that smokers of menthol cigarettes had higher
cotinine levels. This finding would be expected, given
menthol’s inhibition of CYP2A6 metabolism and glucur-
onidation [8,16,17]. As was found with Clark et al [10],
Black/African American subjects had higher cotinine
per cigarette levels, suggesting greater exposure to
nicotine.
Data from the National Health and Nutrition Exami-
nation Survey (NHANES) were used to compare the
serum cotinine levels of more than 1,500 smokers. The
data from this large, nationally representative sample
compared menthol and non-menthol smokers. Menthol
smokers were found to have significantly higher serum
cotinine levels (1333.8 ± 40.1 nmol/L) as compared to
non-menthol smokers (1230.3 ± 24.5 nmol/L) [6].
In an inpatient research study by Ahijevych and col-
leagues [4], plasma samples were taken while the sub-
jects were smoking as desired, followed by several days
of smoking abstinence. Cotinine half-life and did not
significantly differ between menthol (23.1 ± 7.9 hours)
and non-menthol smokers (18.1 ± 8.1 hours) [4]. How-
ever, as has been discussed previously [10,11], there was
a main effect for race, with Black/African American
smokers having greater cotinine levels as compared to
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had greater exposure to nicotine on a per cigarette basis.
A study by Patterson et al (2003) of 190 treatment-
seeking smokers (29 menthol smokers, 161 non-menthol
smokers) failed to find significant differences in nicotine
boost (an individualized measure of how much nicotine
has been extracted from smoking a cigarette) produced
following the smoking a preferred-brand cigarette (p <
0.10). However, the authors note that “the absence of
racial differences in boost and a lack of association with
cigarette characteristics (e.g., menthol) may be attributa-
ble to the relatively small number of African Americans
in the sample” [18]. Consistent with other studies
[4,10,11], being Black/African American was significantly
associated with greater levels of blood nicotine following
a single cigarette. [18]
Mustonen et al [19] investigated possible associations
between cotinine/CPD ratios in subgroups varying by
gender and race/ethnicity in a randomized clinical trial.
Consistent with other studies [4,10,11,18], Black/African
American smokers smoked fewer CPD, but did not have
significantly lower cotinine levels, suggesting a higher
cotinine per cigarette ratio. Although there was a pat-
tern toward higher cotinine levels in smokers of
menthol cigarettes, it was not statistically significant.
There was, however, a significant gender by race by
menthol interaction on salivary cotinine level as well as
cotinine/CPD ratio. Black/African American menthol
cigarette smokers and Black/African American non-
menthol cigarette smoking women had higher cotinine/
CPD ratios than did White smokers. These findings sug-
gest that the relationship between number of cigarettes
consumed and salivary cotinine is complex. This study
was limited in that puffing rate, depth of inhalation and
length of cigarette smoked could not be controlled for
in the study sample. The authors concluded that type of
cigarette, race/ethnicity, and gender need to be evalu-
ated concurrently [19].
Wang et al [20] investigated the effects of menthol
cigarettes on adult smokers’ exposure to nicotine in a
large, cross-sectional study. The menthol cigarette smo-
kers were more likely to be Black/African American and
more likely to be female, which is consistent with the
demographics in other studies (for review, see Ahijevych
and Garrett 2004 [21]). There were no significant differ-
ences in nicotine equivalents (nicotine and five major
nicotine metabolites) per cigarette, leading the research-
ers to conclude that smoking menthol cigarettes does
not increase daily exposure to smoke constituents. No
significant differences were found in serum cotinine
levels between menthol and non-menthol cigarette smo-
kers, suggesting that menthol had no effect on the meta-
bolism of nicotine in the study. Consistent with other
studies [4,10,11,18,19], although the Black/African
American smokers smoked fewer cigarettes per day,
there was no different in serum cotinine levels, suggest-
ing a higher nicotine/cigarette ratio. One limitation of
the study was that only a small proportion of the Black/
African American smokers smoked non-menthol
cigarettes.
In a tobacco industry-associated parallel arm study
designed to investigate whether moderately heavy (≥ 15
CPD) smokers of menthol cigarettes had different bio-
marker levels than non-menthol cigarette smokers, the
researchers failed to find significant differences in urine
levels of nicotine or glucuronidated nicotine metabolites.
Unlike other studies [4,10,11,18,19], they found no sig-
nificant racial/ethnic differences in metabolism [22]. A
limitation of the study was the small number of Black/
African American non-menthol cigarette smokers com-
pared with the number of White non-menthol cigarette
smokers.
Using a stored sample from 255 current smokers from
the Southern Community Cohort Study (65 Black/Afri-
can American men, 65 Black/African American women,
63 White men, 62 White women), comparisons of
serum cotinine levels of menthol and non-menthol smo-
kers were made. There were significant interactions
between gender and race/ethnicity, but no significant
differences were found between menthol and non-
menthol groups [23]. Consistent with previous studies
[4,10,11,18,19], after adjustment for CPD differences,
Black/African American smokers had higher cotinine
levels as compared to white smokers.
In a study of more than 700 Black/African American
light smokers (≤ 5 CPD), menthol smokers did not differ
in plasma cotinine levels when compared to their non-
menthol smoking counterparts. This may be due to a
wide range between the minimum and maximum
plasma cotinine levels across smokers in the study: 5.0
ng/mL versus 937.8 ng/mL [9].
A study by Williams and colleagues [24] compared
cotinine levels of menthol- and non-menthol-smoking
patients with and without schizophrenia. The laboratory
study of 142 people assessed blood cotinine levels dur-
ing a typical smoking day, two minutes after smoking a
usual-brand cigarette. There were no significant differ-
ences when comparing the schizophrenic smokers with
non-schizophrenic smokers. However, menthol smokers
had significantly higher serum cotinine levels as com-
pared to non-menthol smokers (294.3 ng/ml and 238.8
mg/ml, respectively; p = .041). Menthol smokers also
had significantly higher serum nicotine levels (27.2 mg/
ml and 22.4 mg/ml, respectively; p = 0.01) an effect that
appears to be driven by schizophrenic smokers having
significantly higher serum nicotine levels as compared
to non-schizophrenic smokers (p < 0.05). The authors
suggest that the elevated levels observed in menthol
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smoke or menthol-mediated inhibition of nicotine meta-
bolism [24].
Carbon monoxide
Like the nicotine/cotinine data, the data from studies
measuring expired air carbon monoxide (CO) and/or
levels of blood carboxyhemoglobin (a measure of CO
exposure), which are often used as biomarkers to indi-
cate level of exposure to tobacco smoke, are not consis-
tent. Some investigators have found that menthol
cigarette smoking increased CO (as measured by expired
CO, CO boost, or blood carboxyhemoglobin) as com-
pared to non-menthol cigarettes smoke [10,24-26],
whereas other studies, including one associated with the
tobacco industry, have found either no difference in CO
exposure [22,26-29], or a lower level among menthol
smokers [30,31]. Ahijevych et al (1996) that found that
menthol smokers had lower CO measurements as com-
pared to non-menthol smokers, reporting statistically
significant differences for the Black/African American
menthol participants of this women-only study [30].
Possible reasons for the inconsistency of the findings
include the possibility that physiologic variables, such as
mucous layers in mucosal cold nerve endings or differ-
ences in how the cigarette burns (menthol pyrolysis)
may affect CO levels [30,32]. Also, menthol’se f f e c t so n
biomarkers such as blood carboxyhemoglobin and coti-
nine are not linear and, as has been noted by publicly
available internal tobacco industry documents, are
affected by other chemicals in the smoke [33].
Tobacco-specific nitrosamines
Toxins present in tobacco, such as tobacco-specific
nitrosamines (TSNAs), which are known carcinogens,
are also used as biomarkers of tobacco smoke exposure.
Menthol may alter glucuronidation metabolism of some
TSNAs, such as the tobacco carcinogen, 4-(methylnitro-
samino)-1-(3-pyridyl)-1-butanone; (NNAL), which goes
through a glucuronic metabolic pathway to form
NNAL-Glucuronide (NNAL-Gluc) [16]. Thus, inhibition
of the glucuronidation process may result in adverse
effects, such as an accumulation of NNAL.
As a parallel to the findings by MacDougall et al [8] in
an experimental in vitro study, Muscat et al [16] found
that menthol inhibited glucuronidation of NNAL in
human microsomes; however, in an in vivo study of rats
treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
none, or NNK (a TSNA that is metabolized into the
TSNA NNAL), those that received oral menthol showed
increased levels of NNAL metabolites. This suggests
enhanced metabolism. Orally administered menthol
delivered in the absence of the other constituents of
tobacco smoke, as well as generalizing from rats to
humans, makes generalizations regarding the possible
effects of menthol tobacco smoke difficult.
In an in vivo component of the Muscat et al [17]
study mentioned above, urinary ratios of NNAL/NNAL-
Gluc in adult smokers were measured. Smokers of
menthol cigarettes had lower urinary ratios of NNAL/
NNAL-Gluc than smokers of non-menthol cigarettes,
suggesting that menthol inhibited NNAL glucuronida-
tion [17]. Although these findings provide additional
s u p p o r tt h a tm e n t h o lg e n e r a l l y inhibits glururonidation
[7,8] a tobacco industry associated study failed to find
any inhibition of glucuronidation of NNAL [22]. This
parallel-arm study, which measured levels of total
NNAL and NNAL-gluc in the urine of moderately
heavy (≥ 15 CPD) smokers of “light” cigarettes (7–15
mg Federal Trade Commission [FTC] “tar”), failed to
find significant differences when comparing levels in
menthol versus non-menthol smokers [21]. Differences
in urinary metabolites of NNAL between Black/African
American and White smokers have been found in other
studies, but menthol was not specifically investigated as
the cause of these differences [34].
Toxicity and cellular effects
A tobacco industry associated study exposed rats to
menthol or non-menthol cigarette smoke via nose-inha-
lation for 1 hour a day, five days per week for 13 weeks.
Exposure to either type of cigarette smoke produced
reduced body weights and histopathological changes,
including epithelial hyperplasia and/or squamous meta-
plasia in the nasal passages, trachea and larynx, and
lungs and bronchi. Olfactory epithelial degeneration was
also observed. There were no differences in these
changes between the types of cigarette smoke. The only
difference noted between the two groups of rats was
that the non-menthol tobacco smoke–exposed rats had
a dose-related increase in nasal discharge [35].
Menthol appears to alter cell membranes, and the
findings of animal studies have suggested, according to
some, that these changes in cell membrane integrity
may result in an increased potential for tobacco-related
disease [36]. In a study evaluating tobacco smoke effects
on transepithelial electrical resistance (TER; the tight
gap junctions between the human bronchial epithelial
cells), both non-menthol and menthol smoke reduced
TER. This indicates that the gap junctions between the
cells were “loosened” up and integrity was lost, which
suggests that the smoke irritated these cells. Menthol
did not appear alter this effect of tobacco smoke [37]. It
does appear, however, that menthol alters cells’ perme-
ability. Porcine esophageal tissue bathed in a solution
containing menthol and NNK had a markedly lower
permeation rate for NNK, and produced an increase in
tissue reservoir formation. This resulted in significantly
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bly increasing cell exposure to NNK, which is something
that the authors suggest may increase the likelihood of
cancer of the esophagus [36]. Recently, menthol has
been shown to increase permeation of both the tobacco
carcinogen nitrosonornicotine (NNN) and nicotine
across porcine buccal mucosa and floor of the mouth
mucosa [39], which suggests menthol could increase
exposure to NNN and nicotine. It should be noted that
epidemiological studies on menthol cigarettes and can-
cer risk do not support the proposition that these cigar-
ettes confer a risk for cancer above that of non-menthol
cigarettes (see “Tobacco-Related Disease”).
One of the more immediate cellular effects of menthol
on cell membranes is that of cell death (cytotoxicity).
Menthol has been shown to be toxic in in vitro biologic
model systems in normal tissue: it inhibits fatty acid-
induced (receptor-mediated) cell respiration in brown
adipose tissue and increased cellular respiration rate and
osmotic swelling (suggesting deterioration of biologic
membranes) in mitochondria [39]. In a variety of cancer
cell cultures, including gastric SNU-5 cells, melanoma,
myeloma, liver epithelial, neuroendocrine, bladder, and
leukemia cells, as well as cells associated with prostate
cancer and neuroblasoma cells, menthol dose- and time-
dependently inhibits cell proliferation and/or induces
cell death [40-51]. Although there is much evidence sug-
gesting toxicity, it is important to note that this is not a
universal finding (see Gordon et al 1982 [52]). Despite
indications of menthol-induced cytotoxicity in both nor-
mal and diseased cells, when added to cigarettes,
menthol does not appear to enhance the cytotoxicity
already produced by tobacco smoke exposure. Accord-
ing to five tobacco industry associated research studies,
both menthol and non-menthol cigarette smoke have
similar levels of cytoxicity, based on results of short-
term genotoxicity assays [53-57].
Lung function and respiration
On two separate days, 74 smokers (18 menthol smokers,
56 non-menthol smokers) participating in an in-patient
study were allowed to smoke one of their usual brand of
cigarettes. During this time, their breathing patterns
were measured. This tobacco industry associated study
found that the average inhalation tidal ratio (a measure
of lung volume) was 1.52 for menthol smokers and 1.79
for the non-menthol smokers, which suggested menthol
smokers had lower inhalation tidal ratios (p = 0.054).
Mean inhalation volume for menthol smokers was 753
mL, which was lower than for non-menthol smokers,
but this difference was not statistically significant (p =
0.11). Total lung exposure times did not significantly
differ between menthol and non-menthol smokers (4.0
sec and 4.1 sec, respectively; p = 0.85) [58].
Smokers with mild-to-moderate chronic obstructive
pulmonary disease were recruited into the longitudinal
Lung Health Study. A total of 5,886 smokers partici-
pated in this prospective, randomized smoking cessation
trial. Although demographic and population information
did not include information on the number of smokers
who smoked menthol cigarettes or non-menthol cigar-
ettes, it was reported that smoking menthol cigarettes
did not significantly affect the rate of decline in lung
function in Year 1 (p = 0.229) or between Year 1 and
Year 5 (p = 0.64), as measured by spirometry, a modi-
fied ATS-DLD-78 Respiratory Symptoms Questionnaire,
and a calculated methacholine reactivity score (based on
forced expiratory volume). No other comparisons of
menthol and non-menthol smokers were reported [59].
According to a published analysis of publicly available
internal tobacco industry documents, when added to
cigarettes, menthol enables deeper inhalation and may
alter the frequency or volume of inhalation patterns
[60]. Most studies, however, have failed to find any
effects of menthol on respiration (e.g., breathing pat-
terns, nasal resistance). However, despite a lack of phy-
siological effects, inhaled menthol vapor has been
associated with reduced ratings of respiratory discomfort
[61-63]. The dichotomy between sensation and physiolo-
gical response has been noted by the tobacco industry,
which (according to one published analysis of publicly
available internal tobacco industry documents) has con-
cluded that menthol increases the perception of nasal
openness in the absence of actual changes in nasal resis-
tance [60].
Cardiovascular function
Data collected in the longitudinal Coronary Artery Risk
Development in Young Adults (CARDIA) study was
used to prospectively evaluate the effects of cigarette
smoking on atherosclerosis and pulmonary function.
This large scale, 15-year study of Black/African Ameri-
can and White Americans found that menthol and non-
menthol cigarettes were equally harmful. Smokers of
either type of cigarette had increased prevalence of cor-
onary calcification and reduced pulmonary function
[64].
In a rapid-smoking study, there was one racial/ethnic
difference in the cardiovascular response of menthol
versus non-menthol smokers in response to exposure to
menthol cigarette smoke. In this repeated-measures
laboratory study of 28 smokers, Black/African American
menthol smokers had lower increases in heart rate fol-
lowing inhalation of menthol cigarette smoke as com-
pared to Black/African American non-menthol smokers
(4.4% increase and 12.2% increase, respectively). The
increases in heart rate of Black/African American
menthol and non-menthol smokers did not significantly
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smoke [65].
Three laboratory cross-over studies by Ciftci and col-
leagues assessed various cardiovascular outcomes follow-
ing the smoking of two test cigarettes (menthol or non-
menthol). Following the smoking of menthol cigarettes,
there were generally worse cardiovascular outcomes,
including worse ventricular diastolic function [66],
greater increases in heart rate (101.2 bpm compared to
83 bpm), greater increase in systolic blood pressure
(130.7 mmHG compared to 118.0 mmHg), and greater
stiffness of the carotid artery (stiffness index of 5.7 com-
pared to 2.2) [67]; however, there was no difference on
measures of coronary flow reserve [68]. It is not known
whether the participants were usually menthol or non-
menthol smokers.
In a small cross-over laboratory study (n = 22), the
effects of “denicotinized” test menthol and non-menthol
cigarettes on a range of psychophysiologic and subjec-
tive variables were measured in both menthol and non-
menthol smokers. No differences between the groups
were found with respect to most of the variables,
although menthol smokers were found to have a greater
increase in heart rate after smoking the test cigarettes as
compared to non-menthol smokers. Menthol smoke
itself did not have any effects that differed from non-
menthol smoke; however, menthol smokers had greater
increases in heart rate, regardless of test cigarette, as
compared to non-menthol smokers [69]. This appears
to be a smoker difference rather than a menthol versus
non-menthol cigarette difference. Since the nicotine had
been removed from the test denicotinized menthol and
non-menthol cigarettes, this suggests that menthol smo-
k e r sm a yb em o r es e n s i t i v et onon-nicotinic, and even
non-menthol, components of smoking, such as other
chemical components or sensory cues.
Tobacco-related disease
Basic research
Basic research has not found evidence that menthol, by
itself, causes cancer or is mutagenic [70-74]. It may,
however, affect cancers induced by other chemicals.
Three animal studies investigated the effects of menthol
on cancer. A tobacco industry associated study found
that menthol cigarette smoke condensate painted on
mouse skin did not significantly alter tumor incidence,
latency, or multiplicity as compared to non-menthol
cigarette smoke condensate. Both menthol and non-
menthol cigarette smoke condensate produced 3–11
tumors per mouse [75]. A second study examined the
effect of orally administered menthol on cancer of the
large bowel and duodenum in rats, and found that
menthol did not significantly alter the percent of rats
with tumors (50% of control rats, 42% of menthol-
treated rats ) or number of tumors per rat (1.5 tumors
in control rats and 1.2 tumors in menthol-treated rats)
[76]. A third study also examined the effect of orally
administered menthol on carcinogenesis. In a rat mam-
mary carcinogenesis model, rats treated with orally
administered menthol had fewer average number of
tumors per rat (2.0 as compared with 3.3), as well as
longer median tumor latencies (80 days as compared
with 63 days). These data suggest that menthol inhibited
carcinogenesis and acted as a chemopreventive agent
that extended tumor latency [77]. As has been pre-
viously discussed, generalization is difficult, as orally
administered menthol differs greatly from menthol
inhaled as a constituent of tobacco smoke.
Clinical and epidemiological research
Possible interactions between menthol and smoking-
related disease, either as a disease state or on the cellu-
lar level, have been studied. The data do not suggest
that smoking menthol cigarettes is associated with an
altered likelihood of developing cancer. Several studies
have failed to find that menthol cigarette smoking alters
the likelihood of developing several kinds of cancers,
including lung and non-lung smoking related cancers, as
well as cardiovascular disease or coronary heart disease
[78-80] in the population as a whole.
Although some studies specifically discussed the
absence of a menthol x gender x disease interaction
[77,80], other studies have suggested that such an inter-
action may exist. One prospective study of the health of
smokers found that male (but not female) menthol smo-
kers had a modestly increased risk of lung cancer, with
ar e l a t i v er i s ko f1 . 4 5( 9 5 %C I=1 . 0 3 –2.02) [82].
Another case control study suggested a small positive
association between pharyngeal cancer in menthol-
smoking males, but not females (OR = 1.7; 95% CI =
0.8–3.4), but this difference was not statistically signifi-
cant [84]. A third case control study found that menthol
use was not associated with changes in risk for esopha-
geal cancer in males, but suggested that females may
have a modestly increased risk (OR = 2.3; 95% CI =
0.93–5.72). These differences also failed to reach statisti-
cal significance [85]. A fourth case control study sug-
gested that menthol may modestly increase risk of lung
cancer in men with histories of more than 32 pack years
of smoking menthol cigarettes (OR = 1.48; 95% CI =
0.71–3.05), but the findings were not statistically signifi-
cant and limited by the small study size [86].
Many studies have compared Black/African Ameri-
can smokers with White smokers, finding consistently
that the Black/African American smokers are at higher
risk for tobacco-related disease such as lung cancer
[87]. These studies, however, failed to separately assess
menthol as a contributing factor, so although menthol
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clusions could be drawn. Although not discussing
menthol per se, an article by Etzel and colleagues [88]
suggested that the lung cancer risk prevention model
that is generally used may not be appropriate for
Black/African American populations, since the models
were developed in White populations. This is an inter-
esting concept that is included here for discussion pur-
poses, since menthol preference is more common
among Black/African American smokers as compared
to White smokers. Etzel et al developed a multivariate
model of predicting risk of lung cancer in the black
population. Using their model, they state that
“mentholated cigarettes seemed to be protective in
current smokers” [88]; however, this finding was not
statistically significant [88].
Summary
Menthol is a biologically active compound that interacts
with tobacco constituents such as nicotine and NNAL,
and may damage or kill cells. Key findings include:
￿ Data on menthol’se f f e c t so nb i o m a r k e r so fs m o k e
exposure, including nicotine/cotinine, CO (expired CO,
blood carboxyhemoglobin), and some TSNAs are
inconclusive.
￿ Menthol is a biologically active compound that may
damage or kill cells.
￿ Menthol does not appear to alter the cytotoxic
effects of tobacco smoke.
￿ Menthol reduces feelings of respiratory discomfort,
but there are no corresponding physiological effects.
￿ The data regarding the effect of menthol on cardio-
vascular responses to cigarette smoke are inconclusive,
however there is some evidence that smoking menthol
cigarettes may produce worse cardiovascular effects as
compared to nonmenthol cigarettes.
￿ Overall, the data regarding menthol cigarette smoke
and cancer do not support a link between menthol
cigarette smoke and increased risk of cancer, however
there are some limited data that suggest possible
menthol x gender x disease interactions.
Thus, based on the data reviewed in this paper,
menthol cigarettes do not generally appear to be more
harmful than nonmenthol cigarettes; both cigarettes
produce significant negative effects on health outcomes,
including respiratory disease, cardiovascular outcomes
and cancer. However, there is some indication that
menthol cigarettes may result in worse acute cardiovas-
cular outcomes. In addition, there may be subgroups of
smokers that may be more or less sensitive to the health
effects of smoking cigarettes (e.g., race x gender x
menthol interactions). It is interesting to note that
although there were some indications that menthol
smokers may be harmed more by cigarette smoking as
compared to nonmenthol smokers, there were no indi-
cations of the converse.
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